Observational studyRespiratory research2023
Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD.
Observational study in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.
TAKINGCARE - TAcKlING the Needs of Carers of People With Chronic respirAtoRy disEases
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.BMJ open respiratory research · 2026Trial
- Trial
- Mitigating chronic respiratory disease through the lens of multimorbidity: the MARES mixed-methods study protocol.BMJ open · 2026Article
- Article
- Navigating COPD and Bronchiectasis: A COPD Foundation Survey of Differences in Patient-Perceived Health Care Experiences by Sex.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Validity of the Chronic Airways Assessment Test (CAAT) in asthma, asthma+COPD and COPD in NOVELTY.ERJ open research · 2025Article
- The Chronic Airways Assessment Test (CAAT™): Evolution From the COPD Assessment Test (CAT™).Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Cough in pulmonary rehabilitation: a retrospective analysis of responders and nonresponders.ERJ open research · 2025Article
- Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Measuring burden of disease in both asthma and COPD by merging the ACQ and CCQ: less is more?NPJ primary care respiratory medicine · 2024Article
- Unravelling the Information Contained in the Single Items of the COPD Assessment Test for Different Outcomes and Smoking Status in Patients with COPD: Results from COSYCONET.International journal of chronic obstructive pulmonary disease · 2024Observational
- The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort.ERJ open research · 2024Article
- Fixed Airflow Obstruction in Asthma Can Be Identified Early by Low FEF25-75% and is Associated with Environmental Exposure.Journal of asthma and allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT).
methodsThe psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma + COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning and analysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma + COPD and those with COPD.
resultsCAAT items were internally consistent (Cronbach's alpha: > 0.7) within each diagnostic group (n = 510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N = 277, Pearson's correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4-0.7) to strongly (> 0.7) with other PRO measures and weakly (< 0.4) with spirometry measures.
conclusionsCAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice.
trial registrationNCT02760329.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.